Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Miederer

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Nuklearmedizin. Nuclear Medicine|October 8, 2021
Alpha emitting nuclides in nuclear medicine theranosticsMatthias Miederer
Nanomedicine (London, England)|September 16, 2016
Harnessing the potential of noninvasive in vivo preclinical imaging of the immune system: challenges and prospectsMustafa Diken, Stefanie Pektor, Matthias Miederer
Gastroenterology Clinics of North America|November 25, 2010
Molecular imaging of gastroenteropancreatic neuroendocrine tumorsMatthias Miederer, Matthias M Weber, Christian Fottner
Radiologie (Heidelberg, Germany)|August 10, 2022
[Pheochromocytoma and paraganglioma during childhood and adolescence]André Lollert, Matthias Miederer, Alexandra Russo, et al.
Advanced Drug Delivery Reviews|June 3, 2008
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applicationsMatthias Miederer, David A Scheinberg, Michael R McDevitt
Current Radiopharmaceuticals|June 6, 2018
<i>In vivo</i> Evaluation of [<sup>225</sup>Ac]Ac-DOTA<sup>ZOL</sup> for α-Therapy of Bone MetastasesNina Pfannkuchen, Nicole Bausbacher, Stefanie Pektor, et al.
Nuclear Medicine and Biology|August 26, 2016
A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targetingMarian Meckel, Vojtěch Kubíček, Petr Hermann, et al.
Pharmaceuticals (Basel, Switzerland)|April 28, 2023
Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer TherapyRoswitha Runge, Anne Naumann, Matthias Miederer, et al.
Frontiers in Nuclear Medicine|October 2, 2024
DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone MetastasesTilmann Grus, Hanane Lahnif, Nicole Bausbacher, et al.
Clinical Nuclear Medicine|August 18, 2012
One single-time-point kidney uptake from OctreoScan correlates with number of desintegrations measured over 72 hours and calculated for the 6.7 hours half-life nuclide (177)LuMatthias Miederer, Helmut Reber, Andreas Helisch, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Nuklearmedizin. Nuclear Medicine|October 8, 2021
Alpha emitting nuclides in nuclear medicine theranosticsMatthias Miederer
Nanomedicine (London, England)|September 16, 2016
Harnessing the potential of noninvasive in vivo preclinical imaging of the immune system: challenges and prospectsMustafa Diken, Stefanie Pektor, Matthias Miederer
Gastroenterology Clinics of North America|November 25, 2010
Molecular imaging of gastroenteropancreatic neuroendocrine tumorsMatthias Miederer, Matthias M Weber, Christian Fottner
Radiologie (Heidelberg, Germany)|August 10, 2022
[Pheochromocytoma and paraganglioma during childhood and adolescence]André Lollert, Matthias Miederer, Alexandra Russo, et al.
Advanced Drug Delivery Reviews|June 3, 2008
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applicationsMatthias Miederer, David A Scheinberg, Michael R McDevitt
Current Radiopharmaceuticals|June 6, 2018
<i>In vivo</i> Evaluation of [<sup>225</sup>Ac]Ac-DOTA<sup>ZOL</sup> for α-Therapy of Bone MetastasesNina Pfannkuchen, Nicole Bausbacher, Stefanie Pektor, et al.
Nuclear Medicine and Biology|August 26, 2016
A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targetingMarian Meckel, Vojtěch Kubíček, Petr Hermann, et al.
Pharmaceuticals (Basel, Switzerland)|April 28, 2023
Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer TherapyRoswitha Runge, Anne Naumann, Matthias Miederer, et al.
Frontiers in Nuclear Medicine|October 2, 2024
DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone MetastasesTilmann Grus, Hanane Lahnif, Nicole Bausbacher, et al.
Clinical Nuclear Medicine|August 18, 2012
One single-time-point kidney uptake from OctreoScan correlates with number of desintegrations measured over 72 hours and calculated for the 6.7 hours half-life nuclide (177)LuMatthias Miederer, Helmut Reber, Andreas Helisch, et al.
Pageof 9